These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1488 related articles for article (PubMed ID: 32298765)

  • 1. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
    Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
    J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of
    Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
    Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
    Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease.
    Hudert CA; Selinski S; Rudolph B; Bläker H; Loddenkemper C; Thielhorn R; Berndt N; Golka K; Cadenas C; Reinders J; Henning S; Bufler P; Jansen PLM; Holzhütter HG; Meierhofer D; Hengstler JG; Wiegand S
    Liver Int; 2019 Mar; 39(3):540-556. PubMed ID: 30444569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity.
    León-Mimila P; Vega-Badillo J; Gutiérrez-Vidal R; Villamil-Ramírez H; Villareal-Molina T; Larrieta-Carrasco E; López-Contreras BE; Kauffer LR; Maldonado-Pintado DG; Méndez-Sánchez N; Tovar AR; Hernández-Pando R; Velázquez-Cruz R; Campos-Pérez F; Aguilar-Salinas CA; Canizales-Quinteros S
    Exp Mol Pathol; 2015 Apr; 98(2):178-83. PubMed ID: 25597287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program.
    Serper M; Vujkovic M; Kaplan DE; Carr RM; Lee KM; Shao Q; Miller DR; Reaven PD; Phillips LS; O'Donnell CJ; Meigs JB; Wilson PWF; Vickers-Smith R; Kranzler HR; Justice AC; Gaziano JM; Muralidhar S; Pyarajan S; DuVall SL; Assimes TL; Lee JS; Tsao PS; Rader DJ; Damrauer SM; Lynch JA; Saleheen D; Voight BF; Chang KM;
    PLoS One; 2020; 15(8):e0237430. PubMed ID: 32841307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network.
    Namjou B; Lingren T; Huang Y; Parameswaran S; Cobb BL; Stanaway IB; Connolly JJ; Mentch FD; Benoit B; Niu X; Wei WQ; Carroll RJ; Pacheco JA; Harley ITW; Divanovic S; Carrell DS; Larson EB; Carey DJ; Verma S; Ritchie MD; Gharavi AG; Murphy S; Williams MS; Crosslin DR; Jarvik GP; Kullo IJ; Hakonarson H; Li R; ; Xanthakos SA; Harley JB
    BMC Med; 2019 Jul; 17(1):135. PubMed ID: 31311600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
    Tan HL; Zain SM; Mohamed R; Rampal S; Chin KF; Basu RC; Cheah PL; Mahadeva S; Mohamed Z
    J Gastroenterol; 2014 Jun; 49(6):1056-64. PubMed ID: 23800943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
    Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
    J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.
    Zusi C; Mantovani A; Olivieri F; Morandi A; Corradi M; Miraglia Del Giudice E; Dauriz M; Valenti L; Byrne CD; Targher G; Maffeis C
    Dig Liver Dis; 2019 Nov; 51(11):1586-1592. PubMed ID: 31255630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
    Speliotes EK; Yerges-Armstrong LM; Wu J; Hernaez R; Kim LJ; Palmer CD; Gudnason V; Eiriksdottir G; Garcia ME; Launer LJ; Nalls MA; Clark JM; Mitchell BD; Shuldiner AR; Butler JL; Tomas M; Hoffmann U; Hwang SJ; Massaro JM; O'Donnell CJ; Sahani DV; Salomaa V; Schadt EE; Schwartz SM; Siscovick DS; ; ; ; Voight BF; Carr JJ; Feitosa MF; Harris TB; Fox CS; Smith AV; Kao WH; Hirschhorn JN; Borecki IB;
    PLoS Genet; 2011 Mar; 7(3):e1001324. PubMed ID: 21423719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.
    Hotta K; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Chayama K; Nakajima A; Nakao K; Sekine A
    BMC Med Genet; 2010 Dec; 11():172. PubMed ID: 21176169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
    Lin YC; Chang PF; Chang MH; Ni YH
    Am J Clin Nutr; 2014 Apr; 99(4):869-74. PubMed ID: 24477042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non-alcoholic fatty liver disease.
    Grove JI; Thiagarajan P; Astbury S; Harris R; Delahooke T; Guha IN; Aithal GP
    Liver Int; 2018 Oct; 38(10):1832-1838. PubMed ID: 29493856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
    Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
    Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Lim JG; Huh H; Ahn JE; Kim L; Kim NY; Ko JS
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1172-1182. PubMed ID: 38418429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.